DnaNudge secures FDA approval to deploy a Multiplex PCR platform for diagnosing four-in-one respiratory pathogens in Ghana

Medical device approval for multiplex testing platform paves way for NantNudge to lead African roll-out of point-of-care technology

London, United Kingdom, December 14th 2023 – Medical and consumer genetics testing innovator and Imperial College London spin-out, DnaNudge, today announces that it has received approval from Ghana’s Food and Drugs Authority (FDA) to deliver its breakthrough four-in-one, respiratory viruses test for clinical deployment both inside and outside labs in the West African country. The medical device approval paves the way for widespread community use in Ghana – and throughout Africa – of DnaNudge’s rapid point-of-care test, which can accurately detect SARS CoV-2, Flu A, Flu B and Respiratory Syncytial Virus (RSV) on a single ‘Quad’ testing cartridge.

The lab-free, highly multiplexed sample-to-result test offers the capabilities of lab-based PCR diagnostics. Unlike the majority of other nucleic acid point-of-care tests based on isothermal amplification methods, the DnaNudge technology uses gold standard RT-PCR. The Quad cartridge test can detect SARS CoV-2 (the virus that causes COVID-19), the two main types of influenza and RSV in around an hour, helping to ensure infection control in clinical settings and aiding clinicians and care teams in accurate differential diagnosis of these four common respiratory viruses, which can all present with very similar clinical signs and symptoms. 

DnaNudge’s testing platform – including the NudgeBox portable analyser and new multiplex Quad cartridge – were validated by the Ghana FDA for clinical use in Ghana at the Quadushah Medical Diagnostic Centre, a secondary level diagnostic centre with a testing menu covering clinical and molecular assays in Tema, Ghana. The stringent performance assessment assay requirement was carried out by the Clinical Virologist (Alexander Martin-Odoom, PhD) on known positive and negative samples obtained from the Virology Department of the Noguchi Memorial Institute for Medical Research, the national research institute at the University of Ghana. 

Dr Alexander Martin-Odoom, Clinical Virologist at University of Ghana commented: “The opportunity to implement such groundbreaking multiplex point-of-care testing technology in Ghana and – as the gateway to Africa – across the rest of the continent, is truly momentous. I am extremely pleased to be part of this collaboration, which will significantly advance infectious disease research and help realise life-saving, ultra-fast diagnostic tests for the population.”

Graham Cooke, Professor of Infectious Diseases at Imperial College London, who led the initial UK clinical validation of DnaNudge’s COVID-19 test (published in The Lancet Microbe in September 2020) said: "I'm excited to see this technology, whose development was greatly accelerated in response to COVID, start to become more widely available. I think it has the potential to transform a range of clinical pathways as well as provide important information for public and global health services."

In November 2023, DnaNudge announced a landmark commercialisation deal with NantNudge LLC a new entity created to drive transformative genomics and AI point-of-decision technology, founded by world-renowned surgeon, physician, scientist, inventor and philanthropist Dr Patrick Soon-Shiong. The license agreement allows NantNudge to manufacture, sell and supply DnaNudge’s medical and consumer testing technologies and services in key territories, including Africa.

NantNudge will now lead the roll-out of DnaNudge’s award-winning point-of-care technology across Africa, beginning in Ghana, in tandem with an active programme to co-develop with DnaNudge further rapid, out-of-lab testing panels to address critical global health challenges – from serious infectious diseases, precision medicine and oncology to TB, diabetic foot and urinary tract infections, sexually transmitted diseases and anti-microbial resistance tests. DnaNudge is currently underway with a key clinical trial in Africa to validate a new test aimed at revolutionising the treatment of Diabetic Foot Infection and targeted for use in other life and limb-saving wound care applications.

Commenting on the announcement of FDA approval in Ghana, Professor Chris Toumazou FREng FRS FMedSci, co-founder of DnaNudge and founder, Chief Scientist of the Institute of Biomedical Engineering at Imperial College London and Laureate of the UNESCO-Equatorial Guinea International Prize For Research in the Life Sciences said: “This milestone approval in Ghana marks the beginning of what we believe will be a seismic shift in the ubiquitous availability of advanced healthcare technology throughout Africa. In partnership with NantNudge, we are now embarking on the first phase of an extensive programme that will see the deployment of our highly multiplexed technology across villages, towns and cities in Africa, delivering equitable access to improved quality of care for communities and reducing costs, complexity and inefficiency for clinical teams and healthcare providers.”

DnaNudge’s NudgeBox platform technology delivers RT-PCR multiplex testing capabilities that are fast, affordable, and easy to implement in any setting, including non-clinical environments – meeting the global need for ubiquitous, reliable rapid testing at low cost and using minimal resources. DnaNudge’s Quad COVID/RSV/Flu test is the first sample-to-result RT-PCR test for the simultaneous qualitative detection and differentiation of genetic material from the SARS-CoV-2 virus, respiratory syncytial virus, and influenza A and influenza B viruses via a single swab – providing results on-the-spot, directly at the point of need.

DnaNudge’s Lab-in-Cartridge system works by placing a sample swab into a disposable cartridge that can extract RNA. The cartridge is then inserted into the portable NudgeBox for analysis and reverse transcribing to DNA, delivering sample-to-result in around an hour. Testing samples can be collected via nasopharyngeal, nasal only or combined nose and throat swabs. The unique lab-free nature of the DnaNudge system means that the test is ideal for use by healthcare professionals in any setting, including urban and rural environments.


About DnaNudge (
DnaNudge is the developer of the world’s first services to use consumers’ own DNA plus lifestyle factors to nudge people towards healthier choices while shopping. DnaNudge’s services analyse and map users’ genetic profile to key nutrition-related health traits – including obesity, diabetes, hypertension and cholesterol – plus skin-related conditions, enabling customers to be guided by their DNA towards healthier, more personalised product choices as they scan and shop. The service has been developed by world-renowned biomedical engineer Regius Professor Chris Toumazou FRS and published geneticist Dr Maria Karvela.

This ground-breaking DNA testing service created to address an epidemic – obesity and Type 2 diabetes – has been successfully adapted for the fight against a pandemic, with the development of the rapid, lab-free CovidNudge RT-PCR test. CovidNudge can accurately detect COVID-19 and other viruses in around an hour, without the need for a laboratory, and is in use in healthcare settings around the world.

Nicky Denovan, EvokedSet PR
Email: nicky[at]evokedset[dot]com
Phone: +44 (0) 118 328 2916

DnaNudge's NudgeBox portable analyser with Quad testing cartridges.
DnaNudge's NudgeBox portable analyser with Quad testing cartridges.

News Release Index

7th March 2024 - DnaNudge
Could a ‘DNA diet’ help to reduce health risks linked to high blood sugar?

14th December 2023 - DnaNudge
DnaNudge secures FDA approval to deploy a Multiplex PCR platform for diagnosing four-in-one respiratory pathogens in Ghana

6th November 2023 - DnaNudge
NantNudge and DnaNudge Launch a Revolutionary Genomic Handheld Device, with First-Of-Kind Point-Of-Decision, Lab in Cartridge PCR Test

26th July 2023 - AB Cube
AB Cube’s SafetyEasy® Suite cloud-based multivigilance software successfully passes China ICH E2B (R3) testing

13th March 2023 - DnaNudge
DnaNudge forges strategic partnership with Mylab Discovery Solutions to deliver next-generation point-of-decision diagnostics for diabetic foot infections

14th February 2023 - DnaNudge
DnaNudge in pilot with Holland & Barrett: Nutrition and Skincare genetics services now available at leading wellness retailer’s flagship London store

30th November 2022 - Diagnostics for the Real World
Diagnostics for the Real World’s landmark SAMBA machine enters Science Museum Group’s permanent collection and features in major new “Injecting Hope” exhibition

5th October 2022 - Diagnostics for the Real World
Diagnostics for the Real World’s multiplex respiratory virus rapid point-of-care tests approved for sale in New Zealand  

8th July 2022 - EPSRC UK-RAS Network
EPSRC UK-RAS Network Launches Key Whitepaper On State-of-the-Art In Legged Robotics  

17th June 2022 - EPSRC UK-RAS Network
National poll: third of Brits open to trialling the use of robots

26th May 2022 - EPSRC UK-RAS Network
Get Ready for UK Festival of Robotics 2022 (18th-24th June): join the conversation as UK robotics labs open doors to the public

18th May 2022 - Diagnostics for the Real World
Diagnostics for the Real World (DRW) achieves UK technical validation for two multiplex respiratory virus rapid tests

13th May 2022 - EPSRC UK-RAS Network
Robot Lab Live returns for UK Festival of Robotics 2022:  join UK’s top robotics research labs for exclusive live demos – Wednesday June 22nd, 4-6pm BST, UK Robotics YouTube Channel

22nd March 2022 - White City Innovation District
London’s global innovation hub: official launch of White City Innovation District

14th March 2022 - Professor Chris Toumazou
Regius Professor Chris Toumazou named first ever UK winner of the UNESCO-Equatorial Guinea International Prize for Research in the Life Sciences

2nd February 2022 - pharmasol
pharmasol completes merger with PharmaLex Group

11th January 2022 - Hamlyn Centre
Ready, set, robot! National Robot Drawing and Story Competitions for Primary Schoolchildren Now Officially Open For Entries


Hello. Question about our services and how we can help? Please leave us a message and we will get back to you soon. Thanks.